Sou Hu Cai Jing·2026-02-25 16:50Core Insights - AstraZeneca's CEO Pascal Soriot's compensation for 2025 is set to increase to £17.7 million (approximately 164 million RMB), making him one of the highest-paid executives in the FTSE 100 index [1] - Novartis CEO Vas Narasimhan's compensation for 2025 is projected to reach 24.9 million Swiss francs (approximately 220 million RMB), a 30% increase from 2024, marking a new high since he took office in 2018 [2] - The long-term incentive plan for Narasimhan has a payout rate of 188% from 2023 to 2025, valued at 17.3 million Swiss francs [2] Compensation Trends - AstraZeneca's Soriot will receive an annual bonus of up to £4.3 million in 2025, reflecting a 22% increase from 2024 [1] - Novartis's stock price surged from approximately $90 at the end of 2022 to nearly $160 by early 2026, resulting in a total shareholder return of 84%, ranking second among 15 global healthcare peers [2] - Roche's CEO Thomas Schinecker is expected to receive a total compensation of 10.2 million Swiss francs (approximately 90.75 million RMB) in 2025 [2] Other Executive Compensation - Sanofi's CEO Paul Hudson's total compensation for 2025 is disclosed to be valued at €10.9 million (approximately 88.37 million RMB) [2] - Novo Nordisk's new CEO Maziar Mike Doustdar received 20.7 million Danish kroner (approximately 22.46 million RMB) during his initial months in office, while former CEO Lars Fruergaard Jorgensen is set to receive nearly $20 million (approximately 137 million RMB) in 2025, including a severance payment of $6.82 million [3] - U.S. pharmaceutical executives' 2025 compensation details are yet to be disclosed, but historically, they tend to be higher than their European counterparts [3]